Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Clene Inc. (CLNN)

Clene submits NDA to FDA seeking accelerated approval of CNM-Au8 for ALS

Neutral Impact 3 of 5 legal/regulatory Written later

Clene Inc. announced that it submitted a New Drug Application to the FDA earlier in October 2026 seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis (ALS). The filing contains no financial figures and does not state a review timeline. For shareholders, the submission advances the company's lead program toward a possible FDA decision, but approval is not assured.

Key points

  • NDA submitted earlier in October 2026 seeking accelerated approval of CNM-Au8 for ALS
  • Application is based on neurofilament light chain biomarker data and clinical outcomes
  • Company says it continues preparing for the confirmatory Phase 3 RESTORE-ALS study
  • Press release dated October 19, 2026, furnished as Exhibit 99.1

The filing

CompanyClene Inc. (CLNN)
Form8-K, current report
Filed with the SECOct 19, 2026, 8:05 AM ET
Accession number0001437749-26-032882

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.